 |
Home Book Browser | |||
|
|
|||
|
MedicalScienceBooks.com Medical Book Review: Pending full review. Ratings (1-4 , 4 being the highest): Organization of information: 3 Usefulness of book: 3 Suitable for intended audience: 3 Author’s objectives met: 4 Significant number of illustrations: 3 Quality of illustrations: 3
Despite
advancements
in
the
cloning
of
the
total
human
genome,
biomedical
innovations
at
the
patient
level
are
becoming
rare
events.
However,
translational
medicine
is a
burgeoning
science
that
shows
the
potential
to
reverse
the
trend.
This
textbook
will
comprise
a
state-of-the-art
survey
of
translational
medicine,
with
emphasis
on
its
emerging
scientific
backbone,
its
strengths,
and
its
weaknesses.
It
explores
all
aspects
of
preclinical
and
clinical
issues
that
are
relevant
to
the
success
of
translational
pharmaceutical
or
medical
device
or
diagnostic
innovations,
including
target
risk
assessment,
biomarker
evaluation,
and
predictivity
grading
for
both
efficacy
and
toxicity;
early
human
trial
designs
that
are
adequate
to
guide
stop
or
go
decisions
on
the
grounds
of
biomarker
panels;
and
biostatistical
methods
to
analyze
multiple
readout
situations
and
quantify
risk
projections.
The
book
provides
guidance
to
design
smart
profiling
strategies
for
new
approaches
aimed
at
cutting
timelines
and
concentrating
on
the
comparison
of
quality
issues
of
early
developmental
processes
for
pharmaceutical
and
biotechnology
research.
By
furthering
the
substantiation
of
translational
medicine,
creating
awareness
about
its
potential
to
promote
innovations
into
clinical
practice,
and
examining
the
terminology
surrounding
current
biotechnologies,
this
book
hopes
to
create
a
dialogue
about
translational
science
and
what
this
will
mean
for
patient
care
in
the
near
future.
Features:
• Takes a multidisciplinary approach across borders in science: preclinical/clinical
• Analyzes complex multilayered processes both focused and standardized to create blueprints
Table of Contents
1. Introduction and definitions M. Wehling
2. Target identification and validation M. Plebani, M. Zaninotto, G. Lippi, E. Marrer, F. Dieterle, J. Vonderscher, D. Stroncek, P. Jin, E. Wang, J. Ren, F. M. Marincola, J. Kirchheiner, W. Peeters, W. J. M. Derksen, D. P. V. de Kleijn, G. Pasterkamp and M. Grasso 3. Biomarkers M. Wehling, D. Bernardi, M. Plebani, L. Lind, F. Azam, R. Midgley, D. J. Kerr, L. Johansson, A. Meyer-Lindenberg and H. Tost 4. Early clinical trial design F. Azam, R. Midgley, D. J. Kerr and C. Karlsson 5. Pharmaceutical toxicology S. Ernst, S. Boyer and S. Platz 6. Translational science biostatistics G. Ferber and E. Glimm 7. Learning by experience: examples of translational processes in the cardiovascular field M. Wehling.
|
||||
|
Copyright 2010- 2011 ©
BioWeb Concepts. All rights
reserved |
||||
